Regeneron Pharmaceuticals Inc (REGN)

Interest coverage

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Earnings before interest and tax (EBIT) (ttm) US$ in thousands 4,272,300 4,448,500 4,845,000 4,719,500 4,918,200 6,093,600 6,399,300 9,190,200 9,383,100 8,105,000 7,298,800 4,460,200 3,867,300 3,524,400 3,276,100 2,580,200 2,459,300 2,246,400 2,113,400 2,543,700
Interest expense (ttm) US$ in thousands 73,000 72,100 69,600 63,800 59,400 56,100 55,000 56,300 57,300 58,000 70,100 65,400 56,900 48,800 30,300 28,600 30,200 30,900 30,500 29,400
Interest coverage 58.52 61.70 69.61 73.97 82.80 108.62 116.35 163.24 163.75 139.74 104.12 68.20 67.97 72.22 108.12 90.22 81.43 72.70 69.29 86.52

December 31, 2023 calculation

Interest coverage = EBIT (ttm) ÷ Interest expense (ttm)
= $4,272,300K ÷ $73,000K
= 58.52

The interest coverage ratio of Regeneron Pharmaceuticals, Inc. provides insights into the company's ability to cover its interest expenses with its operating income.

Looking at the data provided, the interest coverage ratio for the last four quarters has not been explicitly mentioned for Q4 2023, Q3 2023, Q2 2023, and Q1 2023. However, it is observed that in the previous quarters, the interest coverage ratio was relatively high, with values of 114.81 in Q3 2022, 128.45 in Q2 2022, and 161.72 in Q1 2022.

A high interest coverage ratio indicates that the company is generating significantly more operating income than is required to cover its interest expenses. This suggests that Regeneron Pharmaceuticals, Inc. has a strong ability to meet its interest obligations with its current level of earnings.

While it is unknown how the interest coverage ratio has trended in the recent quarters due to lack of data, the historically high ratios from the previous quarters imply a favorable financial position in terms of managing interest payments. Further monitoring of this ratio in subsequent quarters would provide a more comprehensive understanding of the company's financial health and its ability to withstand interest rate fluctuations.


Peer comparison

Dec 31, 2023


See also:

Regeneron Pharmaceuticals Inc Interest Coverage (Quarterly Data)